Mice treated with indinavir, which induces moderate hyperbilirubinemia by targeting hepatic UGT1A1, had reduced development of hypertension upon Ang II administration compared to mice that did not receive indinavir39. This evidence concerns the gene UGT1A1 and hypertensive disorder.